Balchem/$BCPC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Balchem
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
- Ticker
- $BCPC
- Sector
- Materials
- Primary listing
- NASDAQ
- Employees
- 1,430
- Headquarters
- Montvale, United States
- Website
- www.balchem.com
Balchem Metrics
BasicAdvanced
$5.4B
32.07
$5.30
0.85
$0.96
0.56%
Price and volume
Market cap
$5.4B
Beta
0.85
52-week high
$183.90
52-week low
$147.18
Average daily volume
273K
Dividend rate
$0.96
Financial strength
Current ratio
2.467
Quick ratio
1.291
Long term debt to equity
0.104
Total debt to equity
0.107
Dividend payout ratio (TTM)
18.02%
Interest coverage (TTM)
28.75%
Profitability
EBITDA (TTM)
278.078
Gross margin (TTM)
36.46%
Net profit margin (TTM)
15.41%
Operating margin (TTM)
20.70%
Effective tax rate (TTM)
22.47%
Revenue per employee (TTM)
$780,000
Management effectiveness
Return on assets (TTM)
8.53%
Return on equity (TTM)
13.02%
Valuation
Price to earnings (TTM)
32.073
Price to revenue (TTM)
4.887
Price to book
4.08
Price to tangible book (TTM)
14.54
Price to free cash flow (TTM)
30.447
Free cash flow yield (TTM)
3.28%
Free cash flow per share (TTM)
5.583
Dividend yield (TTM)
0.56%
Forward dividend yield
0.56%
Growth
Revenue change (TTM)
9.42%
Earnings per share change (TTM)
15.98%
3-year revenue growth (CAGR)
6.18%
10-year revenue growth (CAGR)
7.36%
3-year earnings per share growth (CAGR)
18.56%
10-year earnings per share growth (CAGR)
11.72%
3-year dividend per share growth (CAGR)
10.58%
10-year dividend per share growth (CAGR)
10.94%
What the Analysts think about Balchem
Analyst ratings (Buy, Hold, Sell) for Balchem stock.
Analyst projections of the future price of Balchem stock.
Bulls say / Bears say
Balchem delivered record third-quarter sales of $290.7 million, up 8.6%, while net earnings rose 16%; all three reporting segments grew. That breadth suggests growth is not reliant on a single business. (Balchem)
Animal Nutrition and Health sales rose 11.7% and operating earnings climbed 82.8%, as customers adopted encapsulated nutrients. Management also reported growing international demand and launched next-generation encapsulated methionine on 1 October, supporting a technology-led path to further growth. (The Motley Fool)
Third-quarter free cash flow was $57.9 million and net leverage was just 0.2 times, while Balchem repurchased about $127 million of shares over the trailing year. Strong cash generation and low debt leave room for investment and shareholder returns. (Balchem, The Motley Fool)
Higher oil, freight, energy and petrochemical-based input costs are lifting expenses, and management said delays in passing costs through can dilute margins as a percentage of sales. This leaves profitability exposed if costs rise faster than pricing can adjust. (The Motley Fool, Balchem)
Inventory reached $177 million at September, up from $131.4 million at year-end, and management described it as historically high. The build ties up working capital and could become a burden if safety stocks or demand do not unwind as planned. (The Motley Fool)
Balchem's fracking-fluid business is running at an annualised $8 million, compared with $105 million of annual revenue historically. The sharp contraction removes a former revenue contributor, and a rebound is uncertain. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
Balchem Financial Performance
Revenues and expenses
Balchem Earnings Performance
Company profitability
Upcoming events
No upcoming events
Balchem News
AllArticlesVideos
Funds containing Balchem
AllUSDEURGBP
Fund name | Fund size | $BCPC weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.30% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.30% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.19% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.19% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.